View Financial HealthAgilent Technologies 배당 및 자사주 매입배당 기준 점검 4/6Agilent Technologies 수익으로 충분히 충당되는 현재 수익률 0.74% 보유한 배당금 지급 회사입니다.핵심 정보0.7%배당 수익률0.9%자사주 매입 수익률총 주주 수익률1.6%미래 배당 수익률0.9%배당 성장률8.2%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향20%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).모든 업데이트 보기Recent updates공고 • Jul 14Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal AdenocarcinomaAgilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase-nvhy), Bristol Myers Squibb’s PD-1-targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. PD-L1 IHC 28-8 pharmDx, Code SK005, is an FDA-approved diagnostic aid for detecting PD-L1 expression (Combined Positive Score [CPS] = 1) in these tumor types for patients being considered for treatment with OPDIVO® or OPDIVO QVANTIG®. PD-L1 expression is determined using CPS, which measures PD-L1 staining in tumor and immune cells relative to the total number of viable tumor cells. Gastric and esophageal cancers continue to represent a significant global health burden, with high mortality rates and limited long-term survival for many patients. Esophageal cancer is the 11th most common cancer worldwide with over 510,000 new cases and is the seventh leading cause of cancer mortality, accounting for over 445,000 cancer deaths each year. Patients with esophageal cancer have an overall five-year survival of 22%. Gastric cancer is the fifth most common cancer worldwide with around 968,000 new cases and is also the fifth leading cause of cancer mortality, accounting for approximately 660,000 cancer deaths each year. Patients with gastric cancer have an overall 5-year survival of 38%. PD-1- and PD-L1-targeted immunotherapies, including OPDIVO®, have transformed treatment approaches across multiple cancer types, underscoring the importance of accurate biomarker testing to help identify patients who may benefit from these therapies. PD-L1 IHC 28-8 pharmDx was developed by Agilent in partnership with Bristol Myers Squibb as part of the clinical development program supporting OPDIVO®. Clinical studies CheckMate-648 and CheckMate-649 demonstrated improvements in overall survival and progression-free survival in patients with ESCC, gastric, GEJ, and esophageal adenocarcinoma treated with OPDIVO® and OPDIVO QVANTIG®. PD-L1 IHC 28-8 pharmDx is manufactured by Agilent Technologies, Inc.공고 • Jul 08Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic AnalysisAgilent Technologies Inc. announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production. The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity. By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, Agilent Technologies Inc. is expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows. Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities. For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities. The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows. Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally.공고 • Jul 01Agilent Technologies Launches Xcelligence RTCA Esight AI ModuleAgilent Technologies Inc. announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions. Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis. By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise. The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research. By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.공고 • Jun 26Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP.Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for approximately $950 million on March 9, 2026. A cash consideration of $950 million will be paid by Agilent Technologies, Inc. As part of consideration, $950 million is paid towards common equity of Biocare Medical, LLC. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group. For the period ending December 31, 2025, Biocare Medical, LLC reported total revenue of $90 million. The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent’s EPS approximately 12 months following close. Barclays Capital Inc. acted as financial advisor for Agilent Technologies, Inc. Sullivan & Cromwell LLP acted as legal advisor for Agilent Technologies, Inc. Joele Frank is serving as strategic communications adviser to Agilent. Jefferies LLC acted as financial advisor for Biocare Medical, LLC. Ropes & Gray LLP acted as legal advisor for Biocare Medical, LLC. Barclays Bank PLC acted as financial advisor for Agilent Technologies, Inc. ICR Healthcare is serving as strategic communications adviser to Biocare. Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP on June 25, 2026. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).Recent Insider Transactions • Jun 06Independent Director recently sold €186k worth of stockOn the 29th of May, G. Dolsten sold around 2k shares on-market at roughly €116 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €922k more than they bought in the last 12 months.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: AG8 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: AG8 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Agilent Technologies 배당 수익률 vs 시장AG8의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (AG8)0.7%시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.7%업계 평균 (Life Sciences)0.8%분석가 예측 (AG8) (최대 3년)0.9%주목할만한 배당금: AG8 의 배당금( 0.74% )은 German 시장에서 배당금 지급자의 하위 25%( 1.56% )와 비교해 주목할 만하지 않습니다.고배당: AG8 의 배당금( 0.74% )은 German 시장에서 배당금 지급자의 상위 25%( 4.67% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 20.1% )이 낮기 때문에 AG8 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 26.5% )로 AG8 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/27 13:56종가2026/07/24 00:00수익2026/04/30연간 수익2025/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Agilent Technologies, Inc.는 35명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdRobert BambergerBairdCharles ButlerBarclays32명의 분석가 더 보기
Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).
공고 • Jul 14Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal AdenocarcinomaAgilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase-nvhy), Bristol Myers Squibb’s PD-1-targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. PD-L1 IHC 28-8 pharmDx, Code SK005, is an FDA-approved diagnostic aid for detecting PD-L1 expression (Combined Positive Score [CPS] = 1) in these tumor types for patients being considered for treatment with OPDIVO® or OPDIVO QVANTIG®. PD-L1 expression is determined using CPS, which measures PD-L1 staining in tumor and immune cells relative to the total number of viable tumor cells. Gastric and esophageal cancers continue to represent a significant global health burden, with high mortality rates and limited long-term survival for many patients. Esophageal cancer is the 11th most common cancer worldwide with over 510,000 new cases and is the seventh leading cause of cancer mortality, accounting for over 445,000 cancer deaths each year. Patients with esophageal cancer have an overall five-year survival of 22%. Gastric cancer is the fifth most common cancer worldwide with around 968,000 new cases and is also the fifth leading cause of cancer mortality, accounting for approximately 660,000 cancer deaths each year. Patients with gastric cancer have an overall 5-year survival of 38%. PD-1- and PD-L1-targeted immunotherapies, including OPDIVO®, have transformed treatment approaches across multiple cancer types, underscoring the importance of accurate biomarker testing to help identify patients who may benefit from these therapies. PD-L1 IHC 28-8 pharmDx was developed by Agilent in partnership with Bristol Myers Squibb as part of the clinical development program supporting OPDIVO®. Clinical studies CheckMate-648 and CheckMate-649 demonstrated improvements in overall survival and progression-free survival in patients with ESCC, gastric, GEJ, and esophageal adenocarcinoma treated with OPDIVO® and OPDIVO QVANTIG®. PD-L1 IHC 28-8 pharmDx is manufactured by Agilent Technologies, Inc.
공고 • Jul 08Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic AnalysisAgilent Technologies Inc. announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production. The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity. By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, Agilent Technologies Inc. is expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows. Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities. For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities. The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows. Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally.
공고 • Jul 01Agilent Technologies Launches Xcelligence RTCA Esight AI ModuleAgilent Technologies Inc. announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions. Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis. By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise. The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research. By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.
공고 • Jun 26Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP.Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for approximately $950 million on March 9, 2026. A cash consideration of $950 million will be paid by Agilent Technologies, Inc. As part of consideration, $950 million is paid towards common equity of Biocare Medical, LLC. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group. For the period ending December 31, 2025, Biocare Medical, LLC reported total revenue of $90 million. The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent’s EPS approximately 12 months following close. Barclays Capital Inc. acted as financial advisor for Agilent Technologies, Inc. Sullivan & Cromwell LLP acted as legal advisor for Agilent Technologies, Inc. Joele Frank is serving as strategic communications adviser to Agilent. Jefferies LLC acted as financial advisor for Biocare Medical, LLC. Ropes & Gray LLP acted as legal advisor for Biocare Medical, LLC. Barclays Bank PLC acted as financial advisor for Agilent Technologies, Inc. ICR Healthcare is serving as strategic communications adviser to Biocare. Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP on June 25, 2026. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.
Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).
Recent Insider Transactions • Jun 06Independent Director recently sold €186k worth of stockOn the 29th of May, G. Dolsten sold around 2k shares on-market at roughly €116 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €922k more than they bought in the last 12 months.